Irena Rohr1, Robert Zeillinger2, Michaela Heinrich3, Nicole Concin4, Ignace Vergote5, Mani Nassir6, Sven Mahner7, Els VAN Nieuwenhuysen5, Fabian Trillsch7, Dan Cacsire-Tong2, Radoslav Chekerov1, Jalid Sehouli8, Elena I Braicu9. 1. Gynecological Tumor Center and European Competence Center for Ovarian Cancer, Charité-Universitätsmedizin Berlin, Berlin, Germany. 2. Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria Ludwig Boltzmann Cluster Translational Oncology, General Hospital of Vienna, Vienna, Austria. 3. Alice Salomon University of Applied Sciences, Berlin, Germany and Center for Chronic Sick Children, Charité-Universitätsmedizin Berlin, Berlin, Germany. 4. Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria. 5. Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, Leuven, Belgium. 6. Ovarian Cancer Tumor Bank (TOC), Charité-Universitätsmedizin Berlin, Berlin, Germany. 7. Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 8. Gynecological Tumor Center and European Competence Center for Ovarian Cancer, Charité-Universitätsmedizin Berlin, Berlin, Germany jalid.sehouli@charite.de. 9. Gynecological Tumor Center and European Competence Center for Ovarian Cancer, Charité-Universitätsmedizin Berlin, Berlin, Germany Ovarian Cancer Tumor Bank (TOC), Charité-Universitätsmedizin Berlin, Berlin, Germany.
Abstract
BACKGROUND/AIM: IGF-I (insulin growth factor 1) is crucially involved in cellular proliferation. Moreover, deregulation of IGF-I has been shown to be relevant in the carcinogenesis of various tumor entities. However, the impact of IGF-I in epithelial ovarian cancer (EOC) is unclear. In the present study, we investigated the predictive and prognostic role of circulatory IGF-I in primary EOC patients. PATIENTS AND METHODS: In the FP6 European Project "OVCAD", 275 consecutive primary EOC patients were enrolled. Patients were eligible if radical cytoreductive surgery and platinum-based chemotherapy were performed. Plasma IGF-I was detected using ELISA. RESULTS: Increased plasma IGF-I levels were more frequently found in well-differentiated epithelial ovarian carcinoma (p=0.0047). A weak correlation was observed between IGF-I levels and CA-125 in patients with serous EOC (p=0.04). No association between IGF-I expression and other clinico-pathological parameters was observed. CONCLUSION: IGF-I is overexpressed in patients with well-differentiated EOC. Further studies are warranted to elucidate the role of IGF-I in this sub-group of patients. Copyright
BACKGROUND/AIM: IGF-I (insulin growth factor 1) is crucially involved in cellular proliferation. Moreover, deregulation of IGF-I has been shown to be relevant in the carcinogenesis of various tumor entities. However, the impact of IGF-I in epithelial ovarian cancer (EOC) is unclear. In the present study, we investigated the predictive and prognostic role of circulatory IGF-I in primary EOC patients. PATIENTS AND METHODS: In the FP6 European Project "OVCAD", 275 consecutive primary EOC patients were enrolled. Patients were eligible if radical cytoreductive surgery and platinum-based chemotherapy were performed. Plasma IGF-I was detected using ELISA. RESULTS: Increased plasma IGF-I levels were more frequently found in well-differentiated epithelial ovarian carcinoma (p=0.0047). A weak correlation was observed between IGF-I levels and CA-125 in patients with serous EOC (p=0.04). No association between IGF-I expression and other clinico-pathological parameters was observed. CONCLUSION:IGF-I is overexpressed in patients with well-differentiated EOC. Further studies are warranted to elucidate the role of IGF-I in this sub-group of patients. Copyright